Accretion, Synergy and the Walk-Away Price at Vardhman Speciality Chemicals
Vardhman Speciality Chemicals is acquiring Anmol Organics. Vardhman reports PAT of ₹310 crore on 10 crore shares, trades at a P/E of 22 (₹682 per share). Anmol reports PAT of ₹95 crore on 2 crore shares and is asking ₹2,300 crore of equity value, which is 24.2x its earnings. Listed specialty-chemical peers trade at a P/E of 18. The transaction is expected to deliver ₹80 crore of EBITDA synergies from procurement and logistics, phased in fully by year two, against one-off integration costs of ₹120 crore. Vardhman's pre-tax cost of debt is 9.5%; its tax rate is 25%; its cost of capital is 12%. Two structures are on the table: (A) all cash, funded 60% by debt and 40% from balance-sheet cash yielding 6%; (B) an all-share exchange at Vardhman's current market price. The promoter family, holding 51% of Vardhman, is worried about EPS dilution in structure B.
1. Compute the exchange ratio and the EPS accretion/dilution under both structures, with and without synergies.
Read the worked answer
Value per Anmol share = 2,300/2 = ₹1,150 → P/E 24.2x. Exchange ratio (structure B) = 1,150/682 = 1.686 Vardhman shares per Anmol share, i.e. 3.372 crore new shares. Post shares = 13.372 crore. Post-tax synergies = 80 × (1 − 0.25) = ₹60 crore.
| Structure | PAT (₹ crore) | Shares (crore) | EPS (₹) | vs ₹31 |
|---|---|---|---|---|
| Standalone | 310 | 10.00 | 31.00 | - |
| A – all cash | 366.7 | 10.00 | 36.67 | +18.3% |
| A – cash, no synergies | 306.7 | 10.00 | 30.67 | −1.1% |
| B – all share | 465.0 | 13.372 | 34.78 | +12.2% |
| B – all share, no synergies | 405.0 | 13.372 | 30.29 | −2.3% |
Structure A workings. Debt ₹1,380 crore at 9.5% = ₹131.1 crore interest, ₹98.3 crore post-tax. Cash ₹920 crore at 6% opportunity cost = ₹55.2 crore, ₹41.4 crore post-tax. PAT = 310 + 95 + 60 − 98.3 − 41.4 = ₹325.3 crore → EPS ₹32.53, only +4.9%. The cash component materially changes the answer and cannot be ignored.
The lesson. Structure B is dilutive without synergies (30.29 vs 31.00) because 24.2x is paid against an acquirer trading at 22x - exactly as theory predicts. It becomes accretive only because ₹60 crore of post-tax synergy, worth ₹500 crore capitalised at 12%, exceeds the premium. Accretion in structure A is largely a bootstrapping artefact: cheap post-tax debt at 7.1% is financing the purchase of earnings at a 4.1% earnings yield. Accretion is not value creation.
2. Is ₹2,300 crore justifiable? Establish the walk-away price and reconcile it with the EPS accretion.
Read the worked answer
Standalone value of Anmol at the peer multiple of 18x: 95 × 18 = ₹1,710 crore (₹855 per share).
Value of synergies. ₹60 crore post-tax perpetuity at 12% = ₹500 crore. Less integration cost of ₹120 crore (treating it as post-tax cash, ₹90 crore) → net synergy value ₹410 crore.
Maximum justifiable price = 1,710 + 410 = ₹2,120 crore, or ₹1,060 per share, 22.3x earnings.
Premium being paid at ₹2,300 crore = 2,300 − 1,710 = ₹590 crore, against ₹410 crore of synergy value. Net value transfer to Anmol's sellers = ₹180 crore destroyed for Vardhman shareholders. The premium consumes 144% of the synergy value.
Reconciling with the EPS accretion. Structure B without synergies is dilutive; with synergies it is accretive; and it is still value-destructive at ₹2,300 crore. This is the classic trap. EPS accretion measures the accounting effect of combining two earnings streams at a given price; value creation measures whether the price paid is below the present value of what is acquired. Here the accretion is driven almost entirely by the ₹410 crore of synergy, while ₹590 crore is handed over. The two numbers can point in opposite directions, and EPS is the weaker signal.
Sensitivity. If synergies are 30% lower (₹56 crore EBITDA), synergy value falls to ₹287 crore and the walk-away drops to ₹1,997 crore - below the ask by ₹303 crore. Given that procurement synergies depend on Anmol's supplier contracts being assignable (many are not), the downside case should be treated as the planning case.
Recommendation. Do not bid above ₹2,100 crore. If Anmol will not move, walk away; the peer multiple of 18x is a competitive constraint, and a rival acquirer paying 24x faces the same arithmetic.
3. Design a deal structure that protects Vardhman if synergies underdeliver, and address the promoter's 51% holding.
Read the worked answer
Contingent consideration. Offer ₹1,880 crore at closing (cash/share split as negotiated) plus an earnout of up to ₹220 crore payable in Vardhman shares at the end of FY27, contingent on Anmol's EBITDA reaching ₹185 crore (base ₹160 crore plus the ₹80 crore synergy target less a 30% tolerance) and on retention of the top three customers. This caps headline consideration at ₹2,100 crore, inside the walk-away price, and converts the synergy risk into a seller-borne risk. Earnouts should be capped, time-bounded and based on audited, objectively verifiable numbers - EBITDA, not 'synergies realised', which is unverifiable and invites dispute.
Structure mix. A pure share deal preserves cash but is dilutive pre-synergy and issues shares at a 22x multiple to buy at 24.2x. A pure cash deal loads ₹1,380 crore of debt and takes leverage toward 2x EBITDA in a cyclical sector. A 40:60 cash:share mix caps leverage and keeps some alignment.
Promoter stake. Under an all-share deal the promoter falls from 51% to 51 × 10/13.372 = 38.1%, well below the 51% control threshold and below the 26% blocking minority in the worst case if further dilution follows. Even a 50% share component takes them to about 45%. If the family's control objective is real, the cash component must be at least 60%, or the promoter must subscribe to a warrant/warrant-adjacent instrument, or Anmol's sellers must accept non-voting shares for part of the consideration.
Protections. Cap the earnout, exclude change-of-control payments to Anmol management from the synergy definition, require key-man retention for 24 months, and set a completion mechanism (locked box with a leakage covenant) rather than a post-closing working-capital adjustment. Finally, condition closing on consent from Anmol's top five customers - the procurement synergies are only as good as the contracts that survive the change of control.